PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30392741-0	2018	Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-beta-cyclodextrin.	2-Hydroxypropyl-beta-cyclodextrin	126-159	NPC1 like intracellular cholesterol transporter 1	Mus musculus	40-69	
30392741-11	2018	We thus investigated the potential of combining RIPK1 inhibition with 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD) therapy HPbetaCD has been shown to slow neurological disease progression in NPC1 mice, cats and patients.	2-Hydroxypropyl-beta-cyclodextrin	123-131	NPC1 like intracellular cholesterol transporter 1	Mus musculus	191-195	
28383485-6	2017	Additionally, after administration of two different therapy approaches using either a combination of miglustat, 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD) and allopregnanolone or a monotherapy with HPbetaCD, we recorded a remarkable reduction of morphological damages in NPC1-/- mice and an up to four-fold increase of proliferating cells within the olfactory epithelium.	2-Hydroxypropyl-beta-cyclodextrin	112-145	NPC1 like intracellular cholesterol transporter 1	Mus musculus	273-277	
29065825-0	2017	2-Hydroxypropyl-beta-cyclodextrins and the Blood-Brain Barrier: Considerations for Niemann-Pick Disease Type C1.	2-Hydroxypropyl-beta-cyclodextrin	0-34	NPC1 like intracellular cholesterol transporter 1	Mus musculus	83-111	
29065825-3	2017	Animal investigations of 2-hydroxypropyl-beta-cyclodextrins (HPbetaCD) in NPC1 in mice demonstrated that HPbetaCD does not cross the blood-brain barrier in significant amounts but suggested a potential for these complex oligosaccharides to moderately impact CNS manifestations when administered subcutaneously or intraperitoneally at very high doses; however, safety concerns regarding pulmonary toxicity were raised.	2-Hydroxypropyl-beta-cyclodextrin	25-59	NPC1 like intracellular cholesterol transporter 1	Mus musculus	74-78	
29065825-3	2017	Animal investigations of 2-hydroxypropyl-beta-cyclodextrins (HPbetaCD) in NPC1 in mice demonstrated that HPbetaCD does not cross the blood-brain barrier in significant amounts but suggested a potential for these complex oligosaccharides to moderately impact CNS manifestations when administered subcutaneously or intraperitoneally at very high doses; however, safety concerns regarding pulmonary toxicity were raised.	2-Hydroxypropyl-beta-cyclodextrin	61-69	NPC1 like intracellular cholesterol transporter 1	Mus musculus	74-78	
29065825-3	2017	Animal investigations of 2-hydroxypropyl-beta-cyclodextrins (HPbetaCD) in NPC1 in mice demonstrated that HPbetaCD does not cross the blood-brain barrier in significant amounts but suggested a potential for these complex oligosaccharides to moderately impact CNS manifestations when administered subcutaneously or intraperitoneally at very high doses; however, safety concerns regarding pulmonary toxicity were raised.	2-Hydroxypropyl-beta-cyclodextrin	105-113	NPC1 like intracellular cholesterol transporter 1	Mus musculus	74-78